Last month, the Institute for Clinical and Economic Review (ICER) issued a draft report on the cost-effectiveness of bluebird bio’s lovo-cel (lovotibeglogene autotemcel) and Vertex/CRISPR’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback